Clinical Trials Logo

Lung Cancer clinical trials

View clinical trials related to Lung Cancer.

Filter by:
  • Completed  
  • Page 1 ·  Next »

NCT ID: NCT06465797 Completed - Lung Cancer Clinical Trials

Observational Bronchoscopy Video Data Collection Study With Adult Patients

Start date: November 8, 2023
Phase:
Study type: Observational

The primary aim is to develop a software algorithm that has the capacity to detect the normal 18 anatomical structures of the lung by using the position of the scope during the bronchoscopy procedure and using existing bronchoscopy technology.

NCT ID: NCT06457269 Completed - Asthma Clinical Trials

Evaluating the Potential of Large Language Models for Respiratory Disease Consultations

EPLLMMRDC
Start date: October 1, 2023
Phase: N/A
Study type: Interventional

The clinical trial aimes to evaluate multiple large language models in respiratory disease consultations by comparing their performance to that of human doctors across three major medical consultation scenarios. The main question aims to answer are: - How do large language models perform in comparison to human doctors in diagnosing and consulting on respiratory diseases across various clinical scenarios? In three clinical scenarios including the online query section, the disease diagnosis section and the medical explanation section, research assistants or volunteers will be asked to cross-question all LLMs or real doctors using predefined online questions and their own issues. After each questioning session, a short washout period is implemented to eliminate potential biases.

NCT ID: NCT06292052 Completed - Lung Cancer Clinical Trials

Relation Between Tumor-draining Lymph Nodes Metastasis Pattern and Non-small Cell Lung Cancer Neoadjuvant Immunotherapy Effectiveness

Start date: January 1, 2017
Phase:
Study type: Observational

The goal of this retrospective cohort analysis is to discover the impact of the involvement extent of tumor-draining lymph nodes (TDLNs) in patients who received neoadjuvant immunochemotherapy. The main question it aims to answer is the role of TDLN in the prediction of treatment effectiveness. Researches will compare tumor-draining lymph nodes metastasis (mTDLNs) group and non-draining lymph nodes metastasis (mNDLNs) group to see whether different metastatic patterns of mediastinal lymph nodes can indicate the treatment effectiveness.

NCT ID: NCT06168877 Completed - Lung Cancer Clinical Trials

Use of Integrated PET/CT as a First Line Staging and Re-staging Technique in Oncologic Patient.

Start date: October 21, 2009
Phase:
Study type: Observational

Positron emission tomoscintigraphy (PET) and contrast computed tomography (CTmdc) are diagnostic methods widely used in the staging and restaging of neoplastic diseases. In recent years, PET tomographs have been implemented, integrating a CT scanner into the PET tomograph (PET/CT): these tomographs are able to simultaneously acquire the function/metabolism study (PET) and the morgfostructural study (CT). Numerous clinical studies have demonstrated the added diagnostic value of PET/CT compared to PET with consequent effect on the choice of treatment type. In addition to the potential clinical value deriving from the simultaneous execution of the two diagnostic methods, it is necessary to consider the possibility of a reduction in indirect costs deriving from the reduction of days of work lost and costs related to transport, both for the patient and for any companions. The aims of this multicenter observational study are: 1. evaluate the diagnostic accuracy of PET/CT, contrast-enhanced CT and contrast-enhanced PET/CT+CT performed in a single examination session (single staging) in cancer patients (patients suffering from lymphoma and lung cancer). 2. evaluate any psychological, quality of life and economic benefits deriving from carrying out the two diagnostic procedures in a single examination session.

NCT ID: NCT06164574 Completed - Lung Cancer Clinical Trials

Immunotherapy in Uncommon and 20ins EGFR-mut Lung Cancers

Start date: November 1, 2022
Phase:
Study type: Observational

Immunotherapy effectiveness and optimal combination strategy in lung cancers with EGFR uncommon and 20ins mutations was unclear. Based on 627 lung adenocarcinoma patients harboring EGFR mutations and receiving immunotherapy, we reported that patients with EGFR uncommon mutations had better response to immunotherapy, than EGFR 19del/L858R or 20in mutations. Immunotherapy monotherapy or plus chemotherapy was identified as better combination strategy for EGFR uncommon or 20ins mutations, respectively. Higher tumor mutation burden, more M1 macrophage, less Tregs and M2 macrophages infiltration, but not PD-L1 expression was found to be associated with EGFR uncommon mutations, compared to EGFR 19del/L858R or 20in mutations. These findings revealed diverse response and optimal combination strategy of lung adenocarcinoma patients harboring EGFR mutation subtypes, promoting rethinking about current immunotherapy application and prolonging survivals of them.

NCT ID: NCT06161233 Completed - Breast Cancer Clinical Trials

Pilot Study of the eHealth Application "Cancer Patients Better Life Experience" (CAPABLE) - Italy

CAPABLE-IT
Start date: May 16, 2023
Phase: N/A
Study type: Interventional

The purpose of the CAPABLE study is to compare health-related quality of life in renal cell carcinoma patients who use or do not use a mobile-based application to monitor adverse events for cancer treatment at home. As secondary objectives, the study investigates the usability of the system and its generalizability to other cancer types

NCT ID: NCT06136923 Completed - Breast Cancer Clinical Trials

An Exploratory Study to Evaluate Attention Biases in Adults With Multiple Sclerosis, Breast Cancer, and Lung Cancer

Start date: October 19, 2023
Phase: N/A
Study type: Interventional

CT-100 is a platform that provides interactive, software based therapeutic components that may be used as part of a treatment in future software-based prescription digital therapeutics. One class of CT-100 components are Digital Neuro-activation and Modulation (DiNaMo) components. DiNaMo components target key neural systems (including but not limited to systems related to sensory-, perceptual-, affective-, pain-, attention-, cognitive control, social- and self-processing) to optimally improve a participant's health.

NCT ID: NCT06135545 Completed - Lung Cancer Clinical Trials

Bupivacaine Liposome Serrate Anterior Plane Block vs Traditional Thoracic Paravertebral Block

Start date: November 18, 2023
Phase: N/A
Study type: Interventional

In this study, patients will receive bupivacaine liposome serratus anterior plane block or ropivacaine paraspinal block to manage postoperative pain. Follow-up visits will be conducted to investigate the patient's postoperative pain and recovery quality. The investigators hypothesize that the simple and safe serratus anterior plane block with a novel long-acting local anesthetic (bupivacaine liposome) has analgesic efficacy and recovery quality that is not inferior to the currently commonly used bupivacaine paraspinal block.

NCT ID: NCT06132607 Completed - Lung Cancer Clinical Trials

3D Lung Reconstructions Using Open-source Software for Lung Cancer Surgery

3D-LUNG
Start date: December 21, 2022
Phase: N/A
Study type: Interventional

Preoperative three-dimensional (3D) lung reconstructions can reduce intraoperative blood loss, conversion rate, and operation duration. Commercial products predominantly provide these 3D reconstructions, hence the aim of this study was to assess the usability and performance of preoperative 3D lung reconstructions created with open-source software.

NCT ID: NCT06131645 Completed - Lung Cancer Clinical Trials

IASLC Grading System as a Predictor for EGFR-TKI Therapy

Start date: January 1, 2021
Phase:
Study type: Observational

The investigators previously validated the grading system proposed by International Association for the Study of Lung Cancer (IASLC) for invasive nonmucinous lung adenocarcinoma (LADC) for its reproducibility, prognostication function and predictive value of adjuvant chemotherapy (ACT). In this exploratory study, the investigators aimed to investigate the role of IASLC grading system in EGFR tyrosine kinase inhibitor (TKI) therapy selection either as adjuvant or palliative therapy.